12.30

1.40% 0.17

Ocular Therapeutix Inc (OCUL)

Overview News Price History Option Chain Financials Why OCUL Down? Discussions Forecast

Ocular Therapeutix Inc stock is traded at $12.30, with a volume of 1.41M. It is up +1.40% in the last 24 hours and up +6.49% over the past month. Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Previous Close:

$12.13

Open:

$12.2

24h Volume:

1.41M

Relative Volume:

0.62

Market Cap:

$2.14B

Revenue:

$61.10M

Net Income/Loss:

$-138.36M

P/E Ratio:

-9.1111

EPS:

-1.35

Net Cash Flow:

$-90.59M

1W Performance:

-2.54%

1M Performance:

+6.49%

6M Performance:

+75.71%

1Y Performance:

+37.58%

1-Day Range:

$12.03

$12.49

1-Week Range:

$11.68

$12.66

52-Week Range:

$5.80

$12.91

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Name

Ocular Therapeutix Inc

Sector

Healthcare (1157)

Industry

Biotechnology (645)

Phone

781-357-4000

Address

15 CROSBY DRIVE, BEDFORD, MA

Employee

274

Twitter

@OCUTX

Next Earnings Date

2025-03-03

Latest SEC Filings

OCUL's Discussions on Twitter

Compare OCUL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCUL Ocular Therapeutix Inc	12.30	2.14B	61.10M	-138.36M	-90.59M	-1.35
VRTX Vertex Pharmaceuticals Inc	395.12	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	589.48	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.38	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.00	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.67	37.96B	3.81B	-644.79M	-669.77M	-6.24

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-08-25	Initiated	William Blair	Outperform
Mar-18-25	Initiated	RBC Capital Mkts	Outperform
Mar-11-25	Initiated	Needham	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jun-20-24	Upgrade	TD Cowen	Hold → Buy
May-31-24	Resumed	Piper Sandler	Overweight
Feb-09-24	Initiated	BofA Securities	Buy
Apr-21-23	Initiated	Robert W. Baird	Outperform
Aug-10-22	Resumed	Berenberg	Buy
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy
Nov-13-20	Reiterated	Raymond James	Strong Buy
Aug-10-20	Reiterated	H.C. Wainwright	Buy
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Downgrade	Cowen	Outperform → Market Perform
May-21-19	Reiterated	H.C. Wainwright	Buy
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight
Nov-15-18	Initiated	Raymond James	Strong Buy
Sep-07-18	Initiated	Piper Jaffray	Overweight
Oct-24-17	Initiated	Guggenheim	Buy
Jul-26-17	Initiated	H.C. Wainwright	Buy
Jul-12-17	Reiterated	Cantor Fitzgerald	Overweight
Jun-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-10-17	Initiated	Cantor Fitzgerald	Overweight
Nov-15-16	Reiterated	RBC Capital Mkts	Outperform
Aug-11-16	Initiated	JMP Securities	Mkt Outperform
Feb-17-16	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-23-15	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-13-15	Initiated	Morgan Stanley	Overweight

View All

Ocular Therapeutix Inc Stock (OCUL) Latest News

Aug 20, 2025

Ocular Therapeutix Inc. Shows Support at Fibonacci LevelJuly 2025 Outlook & Weekly High Conviction Ideas - newsyoung.net

Aug 20, 2025

Ocular Therapeutix Inc. Stock Poised for Technical ComebackJuly 2025 Closing Moves & Weekly Top Stock Performers List - mustnews.co.kr

Aug 20, 2025

Aug 17, 2025

Ocular gets FDA agreement for registrational trial of Axpaxl - MSN

Aug 17, 2025

Aug 16, 2025

Quant Strategy Flags Ocular Therapeutix Inc. for EntryJuly 2025 Earnings & Community Consensus Picks - newsyoung.net

Aug 16, 2025

Aug 15, 2025

Ocular Therapeutix receives FDA agreement under SPA for registrational trial of AXPAXLI in NPDR - Eyes On Eyecare

Aug 15, 2025

Aug 14, 2025

Ocular Therapeutix at H.C. Wainwright: Strategic Moves in Eye Care By Investing.com - Investing.com Canada

Aug 14, 2025

Aug 13, 2025

Ocular Therapeutix receives FDA agreement under special protocol assessment for registrational trial of AXPAXLI - Ophthalmology Times

Aug 13, 2025

Aug 12, 2025

Ocular Therapeutix™ Receives FDA Agreement Under Special - GlobeNewswire

Aug 12, 2025

Ocular Therapeutix: Strategic Advancements and Market Potential Drive Buy Rating - TipRanks

Aug 12, 2025

Ocular Therapeutix's AXPAXLI: A Game-Changer in Diabetic Retinopathy and Wet AMD Markets - AInvest

Aug 12, 2025

Ocular Therapeutix Receives FDA Agreement for Axpaxl Trial in NPDR Treatment - AInvest

Aug 12, 2025

Ocular Therapeutix secures FDA agreement for diabetic retinopathy trial By Investing.com - Investing.com Australia

Aug 12, 2025

Ocular Therapeutix secures FDA agreement for diabetic retinopathy trial - Investing.com

Aug 12, 2025

Ocular Therapeutix Receives FDA Agreement on AXPAXLI Registrational Trial Design. - AInvest

Aug 12, 2025

Ocular Therapeutix Receives FDA Approval for Registrational Trial of AXPAXLI in NPDR, Plans to Outline Clinical Trial Design at Investor Day - AInvest

Aug 12, 2025

Revolutionary Once-Yearly Eye Treatment Gets FDA Trial Approval: Could Help 9M Diabetic Retinopathy Patients - Stock Titan

Aug 12, 2025

Weaker Q2 Results and Rising Losses Might Change the Case for Investing in Ocular Therapeutix (OCUL) - simplywall.st

Aug 12, 2025

Aug 08, 2025

ETF Channel: ITOT Expected to Reach $154 - AInvest

Aug 08, 2025

Analysts Have Made A Financial Statement On Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Second-Quarter Report - Yahoo Finance

Aug 08, 2025

Aug 07, 2025

Optimistic Buy Rating for Ocular Therapeutix Driven by Promising Clinical Trials and Strategic Decisions - TipRanks

Aug 07, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2025 Earnings Call Transcript - MSN

Aug 07, 2025

RBC Capital Maintains Buy Rating on Ocular Therapeutix with $17 Price Target - AInvest

Aug 07, 2025

Aug 06, 2025

Ocular Therapeutix stock hits 52-week high at 12.38 USD By Investing.com - Investing.com Nigeria

Aug 06, 2025

Ocular Therapeutix stock hits 52-week high at 12.38 USD - Investing.com

Aug 06, 2025

Ocular Therapeutix: Q2 Earnings Snapshot - Huron Daily Tribune

Aug 06, 2025

Ocular Therapeutix 2025 Q2 Earnings Deepening Losses Amid Strategic Momentum - AInvest

Aug 06, 2025